Susan E. Morano
Known title: DirectorCIK: 0001983791
Susan E. Morano's purchase track record
Susan E. Morano has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/25/2026 | BSX | $100K | pending | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| BSX | ▲ Buy | Open Market | 2,040 | $100K | 8/25/2026 | View on chart |
| BSX | ▲ Buy | Grant | 3,800 | $0 | 5/7/2026 | View on chart |
| BSX | ▲ Buy | Grant | 1,281 | $0 | 5/7/2026 | View on chart |
| BSX | ▲ Buy | Grant | 24 | $0 | 3/2/2026 | View on chart |
| BSX | ▲ Buy | Grant | 2,081 | $0 | 5/8/2025 | View on chart |
| BSX | ▲ Buy | Grant | 605 | $0 | 5/8/2025 | View on chart |
| BSX | ▲ Buy | Grant | 1,450 | $0 | 5/9/2024 | View on chart |
| BSX | ▲ Buy | Grant | 421 | $0 | 5/9/2024 | View on chart |
| BSX | ▲ Buy | Grant | 1,626 | $0 | 7/3/2023 | View on chart |
| BSX | ▲ Buy | Grant | 456 | $0 | 7/3/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Boston Scientific (BSX) Faces Catheter Recall Amid Valuation Debate
Boston Scientific announced a recall of 262,686 catheters because of a life‑threatening tip failure risk. The recall adds pressure as analysts note the company needs clear evidence of its turnaround to justify a better valuation. Truist Securities kept its rating but cut its price target to $51, reflecting a more cautious view. The stock has still moved higher than the broader market, indicating mixed investor reactions.
Boston Scientific (BSX) Faces Catheter Recall Amid Valuation Debate. Boston Scientific announced a recall of 262,686 catheters because of a life‑threatening tip failure risk. The recall adds pressure as analysts note the company needs clear evidence of its turnaround to justify a better valuation. Truist Securities kept its rating but cut its price target to $51, reflecting a more cautious view. The stock has still moved higher than the broader market, indicating mixed investor reactions.